| The effect of different doses of vitamin D(3) on markers of vascular health in patients with type 2 diabetes: a randomised controlled trial. | |
| | |
MedLine Citation:
|
PMID: 20596692 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
AIMS/HYPOTHESIS: Low 25-hydroxyvitamin D levels predict future cardiovascular events and are common in patients with type 2 diabetes. We compared the effect of 100,000 and 200,000 IU doses of vitamin D(3) on endothelial function, blood pressure and markers of glycaemic control in patients with type 2 diabetes. METHODS: This was a randomised, parallel group, placebo-controlled trial. Patients with type 2 diabetes and baseline 25-hydroxyvitamin D levels <100 nmol/l were enrolled from community and hospital-based diabetes clinics. Participants were assessed in a university department of clinical pharmacology and received a single oral dose of placebo or vitamin D(3) (100,000 IU or 200,000 IU) at baseline, randomly allocated via numbered bottles prepared offsite; participants and investigators were both blinded to treatment allocation. Endothelial function, office blood pressure, B-type natriuretic peptide, insulin resistance and glycosylated haemoglobin were measured at baseline, and at 8 and 16 weeks. RESULTS: We randomised 61 participants to the three groups (placebo 22, 100,000 IU vitamin D(3) 19, 200,000 IU vitamin D(3) 20). There was no significant difference in the primary outcome of endothelial function at 8 weeks (placebo 5.2%, n = 22; 100,000 IU 4.3%, n = 19; 200,000 IU 4.9%, n = 17) or at 16 weeks. Insulin resistance and glycosylated haemoglobin did not improve with either dose of vitamin D(3). On covariate analysis, systolic blood pressure was significantly lower in both treatment arms than in the placebo group at 8 weeks (placebo 146.4 mmHg, 100,000 IU 141.4 mmHg [p = 0.04 vs placebo], 200,000 IU 136.8 mmHg [p = 0.03 vs placebo]). B-type natriuretic peptide levels were significantly lower in the 200,000 IU group by 16 weeks (placebo 34 pg/ml, 200,000 IU 21 pg/ml, p = 0.02). No significant excess of adverse effects was noted in the treatment arms. CONCLUSIONS/INTERPRETATION: High-dose vitamin D(3) improved systolic blood pressure and B-type natriuretic peptide levels, but not endothelial function, insulin resistance or glycosylated haemoglobin in patients with type 2 diabetes. |
| | |
Authors:
|
M D Witham; F J Dove; M Dryburgh; J A Sugden; A D Morris; A D Struthers |
Publication Detail:
|
Type: Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't Date: 2010-07-02 |
Journal Detail:
|
Title: Diabetologia Volume: 53 ISSN: 1432-0428 ISO Abbreviation: Diabetologia Publication Date: 2010 Oct |
Date Detail:
|
Created Date: 2010-09-02 Completed Date: 2011-01-03 Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 0006777 Medline TA: Diabetologia Country: Germany |
Other Details:
|
Languages: eng Pagination: 2112-9 Citation Subset: IM |
Affiliation:
|
Ageing and Health, Ninewells Hospital, Dundee DD1 9SY, UK. m.witham@dundee.ac.uk |
| Data Bank Information | |
Bank Name/Acc. No.:
|
ISRCTN/ISRCTN50587697 |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Adolescent Adult Aged Aged, 80 and over Blood Glucose / drug effects Blood Pressure / drug effects*, physiology Cholecalciferol / administration & dosage*, therapeutic use Diabetes Mellitus, Type 2 / blood, drug therapy*, physiopathology* Dose-Response Relationship, Drug Double-Blind Method Endothelium, Vascular / drug effects*, physiopathology Enzyme-Linked Immunosorbent Assay Female Hemoglobin A, Glycosylated Humans Insulin Resistance Male Middle Aged Natriuretic Peptide, Brain / blood Treatment Outcome |
| Chemical | |
Reg. No./Substance:
|
0/Blood Glucose; 0/Hemoglobin A, Glycosylated; 114471-18-0/Natriuretic Peptide, Brain; 67-97-0/Cholecalciferol |
| Comments/Corrections | |
Comment In:
|
Nat Rev Endocrinol. 2010 Oct;6(10):533
[PMID:
21080539
]
|
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Identification of undiagnosed type 2 diabetes by systolic blood pressure and waist-to-hip ratio.
Next Document: Prevalence and healthcare costs of diabetic retinopathy: a population-based register study in Sweden...